Upcoming AWS Coverage on Cellectis Post-Earnings Results

LONDON, UK / ACCESSWIRE / December 16, 2016 / Active Wall St. blog coverage looks at the headline from Repligen Corp. (NASDAQ: RGEN) as the Company announced on December 15, 2016, that it has acquired TangenX Technology Corp., maker of the innovative single-use Sius? line of tangential flow filtration (TFF) cassettes and hardware used in downstream biopharmaceutical manufacturing processes. Repligen purchased the company in an all-cash transaction of EUR 37.0 million ($39.0 million). Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.

One of Repligen's competitors within the Biotechnology space, Cellectis S.A. (NASDAQ: CLLS), reported on November 22, 2016, its results for the three-month period ended September 30, 2016 and for the nine-month period ended September 30, 2016. AWS will be initiating a research report on Cellectis in the coming days.

Today, AWS is promoting its blog coverage on RGEN; touching on CLLS. Get all of our free blog coverage and more by clicking on the links below:

http://www.activewallst.com/registration-3/?symbol=RGEN

http://www.activewallst.com/registration-3/?symbol=CLLS

Details on TFF and Sius single-use cassettes

TFF is a rapid and efficient method for separation and purification of biomolecules which is widely used in laboratory, process development, and process scale applications in biopharmaceutical manufacturing. Sius? is an innovative single-use TFF line of cassettes and hardware for lab-scale through process-scale biopharmaceutical manufacturing. Single-use Sius TFF cassettes are designed to deliver superior performance to traditional (reusable) TFF cassettes in a cost-competitive format that provides user-ready convenience and flexibility. Each disposable cassette is delivered pre-sanitized, integrity tested, and ready to be equilibrated and used for tangential flow diafiltration and ultrafiltration processing.

TangenX studies demonstrate that utilizing Sius TFF in downstream processing will typically reduce filter costs by 80%, labor by 50%, and buffer usage by 75%, eliminating non-value added steps of cleaning and flushing. Sius TFF cassettes are interchangeable with filter hardware from multiple manufacturers, simplifying customer trial and adoption of Sius products.

Sius TFF will complement Repligen's OPUS® line of Pre-Packed Chromatography Columns used in downstream purification. The Sius portfolio also strengthens the Company's existing capability in filtration, where its XCell? ATF products are used for perfusion and cell culture intensification in upstream manufacturing processes.

Transaction Details

Before being acquired by Repligen, TangenX was owned and controlled by Novasep Holding SAS of Lyon, France. In 2006, Novasep acquired a majority stake in TangenX, located in Shrewsbury, Massachusetts, USA. Repligen expects sales of TangenX products to achieve double-digit growth and contribute revenue in the range of $7.0 million-$7.5 million for FY17. The company expects the acquisition to be accretive on both a GAAP EPS and adjusted EPS basis in 2017.

Tony J. Hunt, President and Chief Executive Officer of Repligen said:

"This strategic acquisition strengthens our position as a leader in single-use bioprocessing technologies and extends our reach into downstream processes, where disposables are increasingly being adopted by biopharmaceutical manufacturers for the convenience, flexibility and cost advantages that they offer. Our companies share a common culture of innovation, and we look forward to working with the entire TangenX team to drive further growth of this platform and develop next generation products for our customers."

Stock Performance

Following the announcement, Repligen's share price finished yesterday's trading session at $33.53, rising 1.45%. A total volume of 259.87 thousand shares exchanged hands. The stock has surged 58.46% and 11.47% in the last six months and past twelve months, respectively. Furthermore, since the start of the year, shares of the company have gained 18.52%. The stock currently has a market cap of $1.14 billion.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street